Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Orthostatic Changes Upon Apomorphine Dose Initiation in Late Stage Parkinson's Disease Patients. A Dose Escalation Study With a Double-Blind Placebo-Controlled Efficacy Determination at 4 Mg.

NCT00145171 is registered in ClinicalTrials.gov with Mylan Bertek Pharmaceuticals as lead sponsor.

NCT NCT00145171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00145171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Orthostatic Changes Upon Apomorphine Dose Initiation in Late Stage Parkinson's Disease Patients. A Dose Escalation Study With a Double-Blind Placebo-Controlled Efficacy Determination at 4 Mg.
Lead sponsor
Mylan Bertek Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2001
Completion date
August 31, 2002
Enrollment
56
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease